Patients with peripheral artery disease (PAD) are at high risk for myocardial infarction (MI).
P eripheral artery disease (PAD) is a manifestation of systemic atherosclerosis. Compared with patients without PAD, those with PAD have a higher prevalence of comorbidities and atherosclerosis in other vascular beds, such as the coronary vessels. 1 The risk of myocardial infarction (MI)
is elevated in patients with PAD. [2] [3] [4] [5] Traditionally, MI is related to coronary artery disease (CAD) and the rupture of an atherosclerotic plaque resulting in an intraluminal thrombus. Partial or complete occlusion of the vessel decreases the blood flow and leads to myocyte necrosis. Conditions other than CAD, such as tachycardia, bradycardia, respiratory failure, hypotension, or anemia, can contribute to an imbalance of oxygen supply and/or demand with myocardial necrosis, especially in patients with comorbidities. Recent efforts have attempted to improve the diagnosis of MI through a universal definition of MI (UDMI). 6,7 However, to our knowledge, the characterization of type, size, and relevance of MI in a population with PAD has not been extensively evaluated.
In the Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease (EUCLID) trial, 8 13 885 patients with symptomatic PAD were randomly assigned to receive either ticagrelor or clopidogrel. Compared with clopidogrel, ticagrelor did not reduce the risk of the primary efficacy end point-a composite of adjudicated cardiovascular death, MI, or ischemic stroke (hazard ratio, 1.02; 95% CI, 0.92-1.13; P = .65). The risk of MI was not significantly different between the groups (hazard ratio, 1.06; 95% CI, 0.91-1.23; P =.48). This study sought to characterize the incidence and types of MI in patients with PAD from the EUCLID trial. Furthermore, this study aimed to identify factors associated with these events, and determine their association with cardiovascular mortality and acute limb ischemia (ALI).
Methods

Study Design
Data from patients enrolled in the EUCLID trial 8 were included (ClinicalTrials.gov identifier: NCT01732822). Eligible participants had an ankle-brachial index of 0.80 or less or had undergone revascularization of the lower limbs. 9 In the doubleblind, event-driven EUCLID trial, 8 13 885 patients were randomly assigned to receive monotherapy with ticagrelor or clopidogrel. All patients provided written informed consent, and the protocol was approved by ethics committees at participating sites. The EUCLID publications committee approved the post hoc analysis with a waiver of informed consent. For these analyses, we evaluated MI events after randomization and during follow-up irrespective of treatment.
End Point Definitions
Myocardial Infarction Myocardial infarction was adjudicated by a central clinical events committee blinded to treatment assignment. 9 The MI events were characterized by type, electrocardiographic changes, and peak troponin elevation. The MI definitions in the EUCLID trial were based on the third UDMI. 6 Since then, the fourth UDMI has been published with similar definitions. 7 Type 1 MI was defined as spontaneous MI; type 2, MI secondary to an ischemic imbalance; type 3, sudden cardiac death; type 4a, MI related to percutaneous coronary intervention (PCI); type 4b, MI related to stent thrombosis; and type 5, MI related to coronary artery bypass graft (CABG) surgery. For the detailed MI definitions used in the EUCLID trial, see the eMethods in the Supplement. Electrocardiographic changes were classified by ST-segment elevation MI (STEMI) or non-STEMI. Q-wave status was assessed by the site investigator only. The peak troponin elevation was measured as the ratio of the peak value to the upper limit of normal.
Cardiovascular Death
All deaths were adjudicated by the clinical events committee to be either cardiovascular or noncardiovascular in nature. Cardiovascular death included sudden cardiac death, death due to acute MI, death due to heart failure, death due to ischemic stroke, death due to other cardiovascular causes (eg, dysrhythmia unrelated to sudden cardiac death, pulmonary embolism, cardiovascular intervention, aortic aneurysm rupture, or PAD), and deaths for which there was no clearly documented noncardiovascular cause (ie, presumed cardiovascular death). Any death with unknown or uncertain cause within 30 days of an ischemic stroke, MI, or a procedure/ surgery was considered a death due to ischemic stroke, MI, or procedure/surgery, respectively.
Acute Limb Ischemia
Acute limb ischemia was defined as requiring hospitalization with the clinical history of a symptomatic rapid or sudden decrease in limb perfusion. Additionally, either (1) a new pulse deficit with associated new rest pain, pallor, paresthesia, or paralysis or (2) confirmation of arterial obstruction by imaging, intraoperative findings, or pathological evaluation, including amputation findings was required. To assess the association of any MI during follow-up with cardiovascular death and subsequent ALI events, we used a multivariate Cox regression model with MI during follow-up as a time-dependent covariate. Once MI occurred, the indicator for MI was turned on for the remainder of follow-up. Unadjusted and adjusted hazard ratios for the association of MI with cardiovascular death and ALI events were derived. Adjustment variables were based on factors most associated with MI from the multivariate model and on factors identified to be important for cardiovascular death and ALI events (eTable 1 in the Supplement). All P values were 2-sided, and a P value less than .05 was considered statistically significant. All analyses were conducted by the Duke Clinical Research Institute using SAS version 9.4 (SAS Institute).
Results
Cohort and Baseline Characteristics
A total of 13 885 patients were analyzed; 9997 (72.0%) were male, and the median (interquartile range) age was 66 (60-73) years. Myocardial infarction occurred in 683 patients (4.9%; 2.4 MIs per 100 patient-years) during a median follow-up of 30 months. Baseline characteristics of patients with and without MI during the study are presented in Table 1 . Patients with MI were typically older, had more advanced limb symptoms, and more frequently had a history of other cardiovascular conditions and revascularization. Cardiovascular risk factors were more prominent in patients with MI. Most patients were being treated with medications for cardiovascular disease or risk factors (ie, antiplatelet agents, β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and statins). The baseline characteristics of patients by region are shown in eTable 2 in the Supplement. The MI incidence rates per 100 patient-years of follow-up by baseline Rutherford classification were 1.9 for asymptomatic patients (grade 0), 1.8 for patients with mild or moderate claudication (grade I or II), 2.4 for patients with severe claudication (grade III), 3.4 for patients with ischemic rest pain (grade IV), 2.9 for patients with minor tissue loss (grade V), and 2.5 for patients with major tissue loss (grade VI). 
TypesofMI
Types of first MI that occurred in 683 patients during the median follow-up of 30 months were adjudicated by the clinical events committee using the UDMI (Figure 1) . Figure 2 shows the time to first MI, first type 1 MI, and first type 2 MI. The incidence rates of MI by region are shown in eTable 3 in the Supplement. Electrocardiographic changes and the ratio of the troponin I/T peak value to the upper limit of normal for the first MI, first type 1 MI, and first type 2 MI are shown in eTable 4 in the Supplement. A total of 522 of 683 first MIs (76.4%) were non-STEMI. Electrocardiography status was unknown in 98 patients (14.3%).
Q-wave status was assessed by the site investigator only and was available in 413 of 683 patients (60.5%) who had an MI, as adjudicated by the clinical events committee. Of these 413 patients, Q-waves were detected in 22 patients (5.3%). In 66 of 413 patients (16.0%), the site investigator determined that no electrocardiographic data were available for Q-wave assessment.
A peak troponin elevation greater than 10-fold the upper limit of normal was found in 312 of 683 first MIs (45.7%). Peak troponin values tended to be higher in type 1 MI vs type 2 MI (type 1: 221 of 405 [54.6%] with an elevation greater than 10-fold the upper limit of normal; type 2: 70 of 236 [29.7%] with an elevation greater than 10-fold the upper limit of normal).
Factors Associated With MI
The factors independently associated with first MI, first type 1 MI, and first type 2 MI are shown in Table 2 . We identified region, age, diabetes, chronic kidney disease, current tobacco use, prior MI, prior revascularization procedures, severe claudication or prior minor amputation, use of β-blockers or angiotensin receptor blockers, and male sex as major factors associated with MI in this patient population. Most factors associated with first MI were also associated with first type 1 MI or with first type 2 MI. Prior PCI and prior MI were associated with first type 1 MI but not with first type 2 MI. Age, heart failure, sex, pain while at rest, β-blocker use, weight (<80 kg), and transient ischemic attack were associated with first type 2 MI but not with first type 1 MI. The Association With Outcome Table 3 shows the association of MI, type 1 MI, and type 2 MI with cardiovascular death and ALI requiring hospitalization. Myocardial infarction, type 1 MI, and type 2 MI were associated with a 6-fold to 9-fold increased risk of cardiovascular death and a 1.5-fold to 5-fold increased risk of ALI requiring hospitalization.
Discussion
This study characterized the types of MI in a large PAD population. The main findings are (1) 5% of patients with symptomatic PAD experienced MI during a median follow-up of 30 months; (2) most of the first MIs in these patients were type 1 MI (spontaneous) but more than one-third were type 2 MI (secondary), and peak troponin values tended to be higher in type 1 MI vs type 2 MI; 
Risk of MI in Patients With PAD
Patients with PAD have high rates of comorbidities and atherosclerosis in other vascular beds. 1, 3 In registry data, 40%
of patients with PAD had no other vascular bed affected. 10 In the EUCLID trial, 8 55% of patients had PAD only. One-third of patients had a total of 2 vascular beds affected, and 10% of patients had 3 vascular beds affected. Despite these lower rates of atherosclerotic disease in more than 1 vascular bed and the frequent use of drugs for secondary prevention (eg, 75% of patients were receiving statin therapy) in the EUCLID trial, 5% of patients experienced an MI during a median follow-up of 30 months. This is similar to previously described MI rates. 11 It has been described before that death from cardiovascular causes for patients with PAD (even without history of MI) is similar to patients with a prior cardiac event.
3,12 However, many patients with PAD are undertreated. 3 This study confirms the high risk of MI in a large PAD population.
TypesofMI
Risk factors and diagnostic assessment, treatment strategies, and prognostic information are mostly suited for type 1 MI, the typical clinical picture of MI. As expected, most first MIs during follow-up in our study were type 1 MI; however, one-third of first MIs were classified as type 2 MI. This rate seems high in comparison with reports in the literature from other MI populations. In acute coronary syndrome trials with MI adjudication, the proportion of type 4a MI is higher, and the prevalence of type 2 MI can be less than 5%.
13,14
In cohort studies of a high-risk population, the incidence might even be higher than the rates observed here. 15 In a trial subanalysis of more than 20 000 patients with stable atherosclerotic disease (prior MI, 86%; symptomatic PAD, 14%), Kidd et al 16 found that 10% of the MIs were type 2 MI.
Taken together, the incidence of type 2 MI varies among different populations and seems high among patients with PAD. The higher rate in patients with PAD might be explained by the frequent comorbidities among patients with PAD contributing to the occurrence of type 2 MI. 17 The high rate of type 2 MI during follow-up in this study of a PAD population highlights the ongoing need for evidence-based management of type 2 MI. The optimal interpretation of type 2 MI has been somewhat controversial.
18,19 Unfortunately, we had little information about the clinical context of these type 2 MIs that could add to the discussion regarding the differentiation between myocardial injury and MI.
Electrocardiography Criteria, Biomarker, and Size
Overall, the electrocardiography characteristics for first MIs in patients with PAD were similar to reports from general populations. 13, 16, 20 Most first MIs in our study were non-STEMI and were in the highest UDMI category of peak biomarker elevation (greater than 10-fold the upper limit of normal). These observations are similar to results from a mixed population of patients with stable atherosclerosis (symptomatic PAD, 14%). 16 Similar to our observations, type 1 MI tended to be larger than type 2 MI in an acute coronary syndrome trial population.
21
Factors Associated With MI Age, diabetes, atherosclerotic disease, prior procedures, and chronic kidney disease were identified as major factors associated with MI in this patient population and represent known risk factors comparable with those in a general population. 22, 23 We speculate that the reason region is a major factor associated with MI relies on the differences in ascertainment, treatment paradigms, or diagnostic evaluations. We identified differences in the multivariate models for type 1 MI vs type 2 MI. First, in contrast to the model for type 1 MI, the model for type 2 MI did not include history of MI or PCI. History of MI and history of revascularization have been identified as effect modifiers for antiplatelet agents for secondary prevention of thrombotic events, including MI, in trials with patients with atherosclerosis. [24] [25] [26] To our knowledge, the manner in which this effect modification relates to MI type has not been evaluated. Second, there has been discussion about whether the definition of type 2 MI should require CAD. 27-29 S a a b ye ta l 30 reported that up to half of We confirmed these associations in a large PAD population over a median follow-up of 30 months. The risk of cardiovascular death was high for patients with type 2 MI but appeared to be even higher for those with type 1 MI.
Other studies reported opposite trends 16,21 but relied on fewer type 2 MI events, and most patients had prior CAD. Our results highlight the need for further studies to identify and test treatment strategies for type 2 MI to prevent cardiovascular death. Type 2 MI was independently associated with ALI requiring hospitalization. This information may be helpful for clinicians to identify patients at increased risk for these events. Whether this risk simply reflects advanced atherosclerosis or if MI has a causal relationship is unknown. However, there were only 4 ALI events requiring hospitalization after a first type 1 MI and only 8 after a first type 2 MI. The large confidence intervals indicate that these numbers should be interpreted with caution. Although MI treatment is mostly suited for type 1 MI, it seems unlikely that the infarction itself increases the risk for ALI (eg, through heart failure or emboli). Common risk factors or comorbidities not included in our model might explain this increased risk. Whether multidisciplinary care can avoid ALI in these comorbid patients at risk or whether this increased risk would justify revascularization despite low event rates deserves further studies.
Limitations
Our study had limitations. The median follow-up time was 30 months. Rate calculated as the number of events per 100 patient years of follow-up.
